Investors

At a Glance

We are eFFECTOR Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). We believe that our therapeutic approach can inhibit the production of key disease-driving proteins, which tumors have hijacked for their benefit, all while preserving normal cell function. We are currently evaluating our lead product candidate, tomivosertib, a MNK inhibitor, in a randomized, double-blind placebo controlled Phase 2b trial in combination with pembrolizumab in patients with metastatic NSCLC. Zotatifin, our inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. Additionally, we have a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. We plan to evaluate zotatifin as a potential host-directed anti-viral therapy in patients with mild to moderate COVID in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.

We are headquartered in San Diego, California.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Change:
Volume:

12.08.2021 10:00 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.